Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patients

J. H. Mortensen, W. T. van Haaften, M. L. Olesen, M. Karsdal, P. Olinga, G. Dijkstra, A. -C. Bay-Jensen

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)S423-S424
Number of pages2
JournalJournal of Crohn's and Colitis
Publication statusPublished - 1-Feb-2017

Cite this